High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma By Ogkologos - August 20, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... January 10, 2024 Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate... June 15, 2026 In the Name of Pinkness October 8, 2020 How to Keep Your Loved One With Cancer Safe From Infection... December 22, 2022 Load more HOT NEWS ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at... Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... AI and remote monitoring are shaping a new patient journey in...
